Any feedback?
Literature summary for 3.4.11.2 extracted from
- The moonlighting enzyme CD13: old and new functions to target (2008), Trends Mol. Med., 14, 361-371.
Activating Compound
| Activating Compound | Comment | Organism | Structure |
|---|---|---|---|
| additional information | CD13 expression is regulated by differentiation agents, such as phorbol esters, transforming growth factor-beta, interleukin-4 and interleukin-10 | Homo sapiens |
Cloned(Commentary)
| Cloned (Comment) | Organism |
|---|---|
| expressed in Escherichia coli | Homo sapiens |
Crystallization (Commentary)
| Crystallization (Comment) | Organism |
|---|---|
- |
Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| 2',3-dinitroflavone-8-acetic acid | - |
Homo sapiens |  |
| actinonin | - |
Homo sapiens | |
| adhesion/signaling-inducing antibody 452 | - |
Homo sapiens | |
| amastatin | - |
Homo sapiens | |
| anti-CD13 monoclonl antibody WM15 | - |
Homo sapiens | |
| bestatin | ubenimex | Homo sapiens | |
| betulinic acid | - |
Homo sapiens | |
| bradykinin | bradykinin is resistant to hydrolysis by CD13, acting rather as a natural inhibitor | Homo sapiens | |
| coronavirus infection inhibitor Y2-K | - |
Homo sapiens | |
| curcumin | - |
Homo sapiens | |
| ezetimibe | - |
Homo sapiens | |
| icatibant | - |
Homo sapiens | |
| leuhistin | - |
Homo sapiens | |
| LVV-hemorphin-7 | - |
Homo sapiens | |
| additional information | the neuropeptide substance P inhibits enkephalin cleavage by CD13 | Homo sapiens | |
| phebestin | - |
Homo sapiens | |
| probestin | - |
Homo sapiens | |
| puromycin | - |
Homo sapiens | |
Localization
| Localization | Comment | Organism | GeneOntology No. | Textmining |
|---|---|---|---|---|
| membrane | - |
Homo sapiens | 16020 | - |
Metals/Ions
| Metals/Ions | Comment | Organism | Structure |
|---|---|---|---|
| Zn2+ | dependent on | Homo sapiens | |
Molecular Weight [Da]
| Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
|---|---|---|---|
| 160000 | - |
about 160000 Da | Homo sapiens |
| 260000 | - |
the protein present in sera of patients with cholestatic diseases is later found to be a high molecular isoform of CD13 (260 kDa) | Homo sapiens |
Natural Substrates/ Products (Substrates)
| Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| additional information | Homo sapiens | where initial removal of the NH2-terminal dipeptide from CXCL11 by CD26 allows for further truncation by CD13 | ? | - |
? | |
| additional information | Homo sapiens | aminopeptidase N removes N-terminal amino acids from unsubstituted oligopeptides, amide or arylamide, with the exception of peptides with Pro in the penultimate position, the order of favored substrates is Ala>Phe>Tyr>Leu>Arg>Thr>Trp>Lys> Ser>Asp>His>Val | ? | - |
? | |
| additional information | Homo sapiens | CD13 degrades the chemokine CXCL11, downregulates CXCR4 and modulates stromal cell-derived factor-1 (also known as CXCL12)-induced migration | ? | - |
? | |
| additional information | Homo sapiens | CD13 hydrolyzes synthetic oligopeptides corresponding to the N terminus of interleukin-1a, interleukin-1b and interleukin-2, although natural interleukin-2 and G-CSF are resistant to hydrolysis | ? | - |
? | |
| additional information | Homo sapiens | CD13 is a receptor for human coronavirus 229E and human cytomegalovirus | ? | - |
? | |
| additional information | Homo sapiens | in vitro, CD13 participates in the metabolism of glutathione, somatostatin, thymopentin, neurokinin A, splenopentin, nociceptin (orphanin) FQ, and peptides derived from the thrombin receptor | ? | - |
? | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Posttranslational Modification
| Posttranslational Modification | Comment | Organism |
|---|---|---|
| glycoprotein | - |
Homo sapiens |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|
| acute myeloid leukemia cell | - |
Homo sapiens | - |
| alveolar macrophage | - |
Homo sapiens | - |
| bile | - |
Homo sapiens | - |
| CL1-0 cell | - |
Homo sapiens | - |
| dendritic cell | - |
Homo sapiens | - |
| endothelial cell | - |
Homo sapiens | - |
| intestinal epithelium | - |
Homo sapiens | - |
| liver | - |
Homo sapiens | - |
| lymphocyte | - |
Homo sapiens | - |
| monocyte | - |
Homo sapiens | - |
| nervous system | - |
Homo sapiens | - |
| pericyte | - |
Homo sapiens | - |
| renal epithelium | - |
Homo sapiens | - |
| serum | - |
Homo sapiens | - |
| spermatid | - |
Homo sapiens | - |
| synoviocyte | - |
Homo sapiens | - |
| U-937 cell | - |
Homo sapiens | - |
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| angiotensin III + H2O | - |
Homo sapiens | angiotensin IV + L-Arg | - |
? | |
| entactin + H2O | - |
Homo sapiens | ? | - |
? | |
| L-Ala-p-nitroanilide + H2O | - |
Homo sapiens | L-Ala + p-nitroaniline | - |
? | |
| Leu-enkephalin-L-Tyr-Gly + H2O | - |
Homo sapiens | Leu + enkephalin-L-Tyr-Gly | - |
? | |
| Lys-des-Arg9-bradykinin + H2O | - |
Homo sapiens | ? | - |
? | |
| lysyl-bradykinin + H2O | - |
Homo sapiens | ? | - |
? | |
| Met-enkephalin-L-Tyr-Gly + H2O | - |
Homo sapiens | Met + enkephalin L-Tyr-Gly | - |
? | |
| additional information | where initial removal of the NH2-terminal dipeptide from CXCL11 by CD26 allows for further truncation by CD13 | Homo sapiens | ? | - |
? | |
| additional information | aminopeptidase N removes N-terminal amino acids from unsubstituted oligopeptides, amide or arylamide, with the exception of peptides with Pro in the penultimate position, the order of favored substrates is Ala>Phe>Tyr>Leu>Arg>Thr>Trp>Lys> Ser>Asp>His>Val | Homo sapiens | ? | - |
? | |
| additional information | CD13 degrades the chemokine CXCL11, downregulates CXCR4 and modulates stromal cell-derived factor-1 (also known as CXCL12)-induced migration | Homo sapiens | ? | - |
? | |
| additional information | CD13 hydrolyzes synthetic oligopeptides corresponding to the N terminus of interleukin-1a, interleukin-1b and interleukin-2, although natural interleukin-2 and G-CSF are resistant to hydrolysis | Homo sapiens | ? | - |
? | |
| additional information | CD13 is a receptor for human coronavirus 229E and human cytomegalovirus | Homo sapiens | ? | - |
? | |
| additional information | in vitro, CD13 participates in the metabolism of glutathione, somatostatin, thymopentin, neurokinin A, splenopentin, nociceptin (orphanin) FQ, and peptides derived from the thrombin receptor | Homo sapiens | ? | - |
? | |
| tuftsin + H2O | the first peptidic bond of this tuftsin is hydrolyzed by CD13, generating an antagonist that competes for receptor binding and thus regulating tuftsin functions | Homo sapiens | ? | - |
? | |
| Type IV collagen + H2O | - |
Homo sapiens | ? | - |
? | |
Subunits
| Subunits | Comment | Organism |
|---|---|---|
| dimer | x-ray crystallography | Homo sapiens |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| aminopeptidase N | the enzyme is named aminopeptidase N because of its preference for neutral amino acids | Homo sapiens |
| APN | - |
Homo sapiens |
| CD13 | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
